VISEN Pharmaceuticals (HKG:2561)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
24.78
-0.20 (-0.80%)
Apr 2, 2026, 3:47 PM HKT
Market Cap2.62B
Revenue (ttm)921.55K
Net Income-237.56M
EPS-2.45
Shares Out105.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,700
Average Volume16,925
Open24.90
Previous Close24.98
Day's Range24.56 - 26.00
52-Week Range24.00 - 54.95
Betan/a
RSI28.77
Earnings DateMar 12, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy f... [Read more]

Sector Healthcare
Founded 2018
Employees 54
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2561
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements